Scleroderma, Systemic Withdrawn Phase 2 Trials for Rituximab (DB00073)

Also known as: Systemic Scleroderma

IndicationStatusPhase
DBCOND0028174 (Scleroderma, Systemic)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01047072Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic SclerosisTreatment